Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Blood

Volumn 112, Issue 8, 2008, Pages 3500-3507

  Lee, Stephanie J ^a,b,h   Kukreja, Manisha ^b   Wang, Tao ^b   Giralt, Sergio A ^c   Szer, Jeffrey ^d   Arora, Mukta ^e   Woolfrey, Ann E ^e   Cervantes, Francisco ^f   Champlin, Richard E ^c   Gale, Robert Peter ^g   Halter, Joerg ^h   Keating, Armand ⁱ   Marks, David I ^j   McCarthy, Philip L ^k   Olavarria, Eduardo ^l   Stadtmauer, Edward A ^m   Abecasis, Manuel ⁿ   Gupta, Vikas ⁱ   Khoury, H Jean ^o   George, Biju ^p   Hale, Gregory A ^q   Liesveld, Jane L ^r   Rizzieri, David A ^s   Antin, Joseph H ^t   Bolwell, Brian J ^u   Carabasi, Matthew H ^v   Copelan, Edward ^u   Ilhan, Osman ^w   Litzow, Mark R ^x   Schouten, Harold C ^y   Zander, Axel R ^z   Horowitz, Mary M ^b   Maziarz, Richard T ^aa   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^f HOSPITAL CLÍNIC   (Spain)

^g Center for Advanced Studies in Leukemia   (United States)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^k ROSWELL PARK CANCER INSTITUTE   (United States)

^l HAMMERSMITH HOSPITAL   (United Kingdom)

^m HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^o EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p CHRISTIAN MEDICAL COLLEGE   (India)

^q ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^r UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^s DUKE UNIVERSITY MEDICAL CENTER   (United States)

^t DANA FARBER CANCER INSTITUTE   (United States)

^u LERNER RESEARCH INSTITUTE   (United States)

^v THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^w ANKARA UNIVERSITY   (Turkey)

^x MAYO CLINIC   (United States)

^y MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^z UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^aa OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMATINIB; METHOTREXATE; TACROLIMUS; ANTINEOPLASTIC AGENT; HLA ANTIGEN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ADOLESCENT; CHILD; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PRESCHOOL CHILD; REGISTER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REGISTRIES; TREATMENT OUTCOME;

EID: 54049146732     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-141689     Document Type: Article

References (24)

1. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation tor chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood. 2000;95: 2219-2225.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
3. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
4. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110:2828-2837.
5. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood. 2007;109:4686-4692.
6. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137:461-467.
7. Ruiz-Arguelles GJ, Gomez-Almaguer D, Morales-Toquero A, et al. The early referral for reducedintensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant. 2005;36:1043-1047.
8. Gratwohl A, Baldomero H, SchwendenerA, Gratwohl M, Urbano-Ispizua A, Frauendorfer K. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe: impact of cost considerations. Leukemia. 2007;21:383-386.
9. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043.
10. Hansen JA, GooleyTA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia [see comments]. N Engl J Med. 1998;338:962-968.
11. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91:513-521.
12. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
13. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908-916.
14. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood. 2004;104:1094-1099.
15. Shimoni A, Kroger N, Zander AR, etal. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia. 2003;17:290-297.
16. Zaucha JM, Prejzner W, Giebel S. et al. Imatinib therapy before myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2005; 36:417-424.
17. Perz JB, Khorashad JS, Marin D, Apperley JF, Olavarria E. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica. 2006;91:1145-1146.
18. Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplantrelated mortality. Haematologica. 2006;91:452-459.
19. Bornhauser M, Kroger N, Schwerdtfeger R, et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol. 2006;76:9-17.
20. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109:1782-1789.
21. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
22. Gooley TA, Leisenring W, CrowleyJ, StorerBE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
23. Klein JP, Moeschberger ML. Survival Analysis: Statistical Methods for Censored and Truncated Data. New York, NY: Springer-Verlag; 2003.
24. Schmitz N, Eapen M, Horowitz MM, et al. Longterm outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006;108:4288-4290.